Unjoni Ewropea - Malti - EMA (European Medicines Agency)

les laboratoires servier - irinotecan anhydrous free-base - neoplażmi pankreatiċi - aġenti antineoplastiċi - trattament ta ' adenocarcinoma metastatic ta-pancreas, flimkien ma ' 5 fluorouracil (artikolu 5) u leucovorin (lv), fil-pazjenti adulti li wettqu wara gemcitabine bbażati fuq terapija.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

nektar therapeutics uk limited - etirinotecan pegol - neoplażmi tas-sider - aġenti antineoplastiċi - it-trattament tal-kanċer tas-sider b'metastasi fil-moħħ.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

pharmaand gmbh - rucaparib camsylate - neoplażmi fl-ovarji - aġenti antineoplastiċi - rubraca is indicated as monotherapy for the maintenance treatment of adult patients with advanced (figo stages iii and iv) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. rubraca huwa indikat bħala monoterapija għall-kura ta 'manteniment ta' pazjenti adulti b'sensittiva għall-platinum rkadew grad għoli ta 'l-epitilju ta' l-ovarji, l-tubu fallopjan, jew primarja peritoneali-kanċer li huma fir-rispons (sħiħa jew parzjali) ' kimoterapija bbażata fuq platinum.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

eli lilly nederland b.v. - ramucirumab - neoplażmi fl-istonku - aġenti antineoplastiċi - - istonku cancercyramza flimkien ma 'paclitaxel huwa ndikat għall-kura ta' pazjenti adulti bil-kanċer gastriku avvanzat jew gastro-esofagali junction adenokarċinoma mal-progressjoni tal-marda wara qabel il-platinu u l-fluworopirimidina-kimoterapija. cyramza monoterapija hija indikata għat-trattament ta 'pazjenti adulti bil-kanċer gastriku avvanzat jew gastro-esofagali junction adenokarċinoma mal-progressjoni tal-marda wara qabel l-platinum jew fluoropyrimidine-kimoterapija, li għalihom trattament flimkien ma' paclitaxel mhix xierqa. tal-kolorektum cancercyramza, flimkien ma 'folfiri (irinotecan, l-aċidu foliniku, u 5‑fluorouracil), huwa indikat għall-kura ta' pazjenti adulti b'kanċer metastatiku tal-kolorektum (mcrc) mal-progressjoni tal-marda jew wara terapija ta 'qabel ma' bevacizumab, oxaliplatin u fluworopirimidina. taċ-ċelluli mhux żgħar tal-pulmun cancercyramza flimkien ma 'docetaxel huwa indikat għall-kura ta' pazjenti adulti b'lokalment avvanzat jew metastatiku taċ-ċelluli mhux żgħar tal-pulmun il-kanċer mal-progressjoni tal-marda wara ibbażat fuq il-platinu ' kimoterapija. epatoċellulari carcinomacyramza monoterapija hija indikata għat-trattament ta 'pazjenti adulti b'avvanzat jew wara falliment ta' karċinoma epatoċellulari li għandhom fis-serum alpha-fetoprotein (afp) ta ' ≥ 400 ng/ml u li kienu kkurati minn qabel b'sorafenib.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

nordic group b.v. - tegafur, gimeracil, oteracil - neoplażmi fl-istonku - aġenti antineoplastiċi - teysuno is indicated in adults:- for the treatment of advanced gastric cancer when given in combination with cisplatin (see section 5. - as monotherapy or in combination with oxaliplatin or irinotecan, with or without bevacizumab, for the treatment of patients with metastatic colorectal cancer for whom it is not possible to continue treatment with another fluoropyrimidine due to hand-foot syndrome or cardiovascular toxicity that developed in the adjuvant or metastatic setting.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

amgen europe b.v. - panitumumab - neoplażmi kolorettali - aġenti antineoplastiċi - vectibix is indicated for the treatment of adult patients with wild-type ras metastatic colorectal cancer (mcrc): , in first-line in combination with folfox or folfiri. , fil-tieni linja f'kombinazzjoni ma ' folfiri għall-pazjenti li rċevew l-ewwel linja bbażata fuq fluoropyrimidine-kimoterapija (esklużi l-irinotecan). , bħala monoterapija wara falliment ta 'l-fluworopirimidina, oxaliplatin u irinotecan-korsijiet ta' kimoterapija li fiha.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

sanofi winthrop industrie - aflibercept - neoplażmi kolorettali - aġenti antineoplastiċi - kura tal-kanċer metastatiku tal-kolorektum (mcrc).

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

cheplapharm arzneimittel gmbh - capecitabine - colonic neoplasms; breast neoplasms; colorectal neoplasms; stomach neoplasms - aġenti antineoplastiċi - xeloda huwa indikat għall-kura awżiljarja ta 'pazjenti wara kirurġija ta ' stadju iii (dukes' stadju c) kanċer tal-kolon. xeloda huwa indikat għall-kura ta ' kanċer metastatiku tal-kolorektum. xeloda huwa indikat għall-kura preferita tal-kanċer gastriku avvanzat flimkien ma ' reġim ibbażat fuq il -. xeloda flimkien ma 'docetaxel huwa indikat għall-kura ta' pazjenti b'lokalment avvanzat jew tal-kanċer tas-sider metastatiku wara l-falliment tal-kimoterapija ċitotossika. it-terapija ta 'qabel kellha tinkludi anthracycline. xeloda huwa wkoll indikat bħala monoterapija għall-kura ta 'pazjenti b'lokalment avvanzat jew tal-kanċer tas-sider metastatiku wara l-falliment ta' taxanes u ta 'kors ta' kimoterapija li fihom jew li għalihom l-aktar anthracycline ma tkunx indikata t-terapija.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - capecitabine - stomach neoplasms; breast neoplasms; colonic neoplasms; colorectal neoplasms - capecitabine - capecitabine huwa indikat għat-trattament awżiljarju ta 'pazjenti wara kirurġija ta' stadju iii (dukes 'stage-c) kanċer tal-kolon. capecitabine huwa indikat għat-trattament tal-kanċer metastatiku tal-kolorektum. capecitabine huwa indikat għall-kura preferita tal-kanċer gastriku avvanzat flimkien ma ' reġim ibbażat fuq il -. capecitabine flimkien ma 'docetaxel huwa indikat għall-kura ta' pazjenti b'lokalment avvanzat jew tal-kanċer tas-sider metastatiku wara l-falliment tal-kimoterapija ċitotossika. it-terapija ta 'qabel kellha tinkludi anthracycline. capecitabine huwa wkoll indikat bħala monoterapija għall-kura ta 'pazjenti b'lokalment avvanzat jew tal-kanċer tas-sider metastatiku wara l-falliment ta' taxanes u ta 'kors ta' kimoterapija li fihom jew li għalihom l-aktar anthracycline ma tkunx indikata t-terapija.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

samsung bioepis nl b.v. - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - aġenti antineoplastiċi - aybintio in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. aybintio in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. għal aktar informazzjoni dwar l-istatus tal-fattur tat-tkabbir tal-epidermide tal-bniedem 2 (her2), jekk jogħġbok irreferi għat-taqsima 5. 1 of the smpc. aybintio in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracyclinecontaining regimens in the adjuvant setting within the last 12 months should be excluded from treatment with aybintio in combination with capecitabine. għal aktar informazzjoni dwar l-istatus ta 'her2, jekk jogħġbok irreferi għat-taqsima 5. 1 of the smpc. aybintio, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. aybintio, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations (see section 5. 1 of the smpc). aybintio in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. aybintio, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. 1 of the smpc). aybintio, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. aybintio, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents (see section 5. 1 of the smpc). aybintio, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5. 1 of the smpc).